Key Insights

Highlights

Success Rate

80% trial completion

Published Results

11 trials with published results (9%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

10.1%

12 terminated out of 119 trials

Success Rate

80.0%

-6.6% vs benchmark

Late-Stage Pipeline

3%

4 trials in Phase 3/4

Results Transparency

23%

11 of 48 completed with results

Key Signals

11 with results80% success12 terminated

Data Visualizations

Phase Distribution

99Total
Not Applicable (26)
Early P 1 (2)
P 1 (29)
P 2 (38)
P 3 (3)
P 4 (1)

Trial Status

Completed48
Recruiting26
Unknown15
Terminated12
Active Not Recruiting11
Suspended3

Trial Success Rate

80.0%

Benchmark: 86.6%

Based on 48 completed trials

Clinical Trials (119)

Showing 20 of 20 trials
NCT04847063Phase 1Recruiting

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

NCT04329494Phase 1Recruiting

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

NCT05700656Phase 1Active Not Recruiting

Galunisertib Combined With Capecitabine in Advanced CRC With PM

NCT04840264Phase 2Recruiting

Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction

NCT05277766Phase 1Active Not RecruitingPrimary

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

NCT05185947Phase 2Completed

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

NCT07001748Phase 2Recruiting

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

NCT02759588Phase 1Completed

Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

NCT04107077Phase 2Recruiting

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

NCT04811703Phase 1Recruiting

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer

NCT06504147Phase 2RecruitingPrimary

A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

NCT07593261Phase 2Not Yet RecruitingPrimary

MRI-Guided Adaptive Radiotherapy for Limited Peritoneal Metastases (MARACAS Trial).

NCT07487168Phase 1Not Yet RecruitingPrimary

Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors

NCT05913674Phase 2RecruitingPrimary

Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)

NCT03127774Phase 2Active Not Recruiting

Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma

NCT04034251Phase 2Terminated

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

NCT04929015Not ApplicableSuspended

Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)

NCT03732768Phase 1CompletedPrimary

Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis

NCT04220827Phase 1Active Not Recruiting

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

NCT04779554Phase 2RecruitingPrimary

Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC

Scroll to load more

Research Network

Activity Timeline